Drug Profile
NI 308
Alternative Names: NI-308Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Developer Biogen; Neurimmune Therapeutics
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Dementia
Most Recent Events
- 07 Dec 2022 NI 308 is still in preclinical trials for Amyotrophic-lateral-sclerosis and Dementia in Switzerland (Neurimmune pipeline, December 2022)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Switzerland
- 28 Jun 2022 No recent reports of development identified for preclinical development in Dementia in Switzerland